RaQualia Pharma is a research and development-based pharmaceutical company whose aim is to create new pharmaceutical products with cutting-edge science and technology focusing on medical fields where patients have the greatest need. We create development compounds, the seeds for new drugs, via an open collaboration network which we have designed. We then deliver valuable new treatments to patients by licensing these compounds to partners who in turn bring that innovation to market.

RaQualia Pharma firmly believes that "innovation will be achieved via an open collaboration network among academia and the private sector." Our knowledge gained from diverse experiences, together with our common mindset, will enable the implementation of a transcendent collaboration network that leaps industry barriers and serves as the driving force for effective and efficient research and development of new drugs.

RaQualia Pharma is different from most start-up companies in many ways. Open collaboration and trust are the heart of our strength and our business model.

1. 

   Human resources

   A group of researchers with broad experiences and a solid record of achievements in developing medications

   A management team that understands the needs of global customers

   Portfolio

   Consistent creation of new development compounds

   Expansion of market potential by adding new target indications

   Improvement of the probability of commercialization by rapid confirmation of product concepts

   Infrastructure

   A comprehensive research support structure and the most advanced research facility

   Growth Potential

   The ability to produce two new development compounds per year

2. 

   The foundation of RaQualia Pharma's business model is the Integrated Open Collaboration Network (IOCN). IOCN does not distinguish between external and internal company resources. All employees focus on innovation and, by cooperating with partners both inside and outside the company, make high and sustained productivity possible. RaQualia Pharma's core competence is to rapidly, efficiently, and effectively create research programs and development candidate compounds. We actively seek opportunities for partnership via licensing and joint development in all of these programs and at all research stages. This model is the driving force behind improving value for patients, our customers, investors and shareholders.

   IOCN is based on trust with our partners. Building trust among our colleagues, in other words both within RaQualia and between RaQualia and companies, customers, partners and stakeholders, is the foundation.

3. 

   RaQualia Pharma operates with a unique organizational structure. Our organization is flat and management comprises a single layer. Management and team members participate in decisionmaking, which allows for swift and cohesive decision making. There are no lines drawn between project teams: the power of the entire organization is focused on innovation.